---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-044406"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:01:06.786663+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics enters $300M ATM equity offering with Jefferies; terminates prior $175M ATM

## Summary
- New Open Market Sale Agreement with Jefferies LLC allows sale of up to $300M in common stock.
- Proceeds to fund clinical development of veligrotug and other candidates, plus commercialization preparation.
- Prior $175M ATM agreement terminated; $115.2M of shares sold under it.
- Jefferies will receive up to 3% commission on gross proceeds; no obligation to sell shares.
- Company may suspend or terminate sales at any time.

## SEC filing metadata
- accession: 0001193125-25-044406
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525044406/0001193125-25-044406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525044406/d909216d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-044406
- JSON: https://secwatch.observer/filing/0001193125-25-044406.json
- Plain text: https://secwatch.observer/filing/0001193125-25-044406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.